The Relationship Between The Expression Of CD33 And CD13 And The Prognosis Of Patients With Multiple Myeloma

Objective To study the expression of CD33 and CD13 in patients with primary multiple myeloma（MM）and to investigate the relationship between CD33 and CD13 and the prognosis of patients with primary MM.Methods A retrospective study of 121 patients with MM initially diagnosed from January 2014 to January 2020 was conducted to explore the expression of CD33 and CD13 in patients,and all patients were followed for overall survival（OS）time and progression-free survival（PFS）time to further explore the relationship between CD33and CD13 expression and the prognosis of MM patients.Results 1.Among the 121 newly diagnosed MM patients,there were 30 patients（24.8%）in the CD33⁺group and 12 patients（9.9%）in the CD13⁺group.2.Kapl an-Meier analysis showed that the PFS time and OS time were significantly shortened in MM patients in CD33⁺group（PFS 17.5 vs 23 months,P=0.000;OS 18.5 vs 25 months,P=0.000）;and the PFS time and OS time were also significantly shortened in MM patients in the CD13⁺group（PFS 21 vs 22 months,P=0.012;OS 25 vs 26 months,P=0.006）.3.Cox regression analysis showed that CD33 and CD13 were independent adverse prognostic factors in MM patients（CD33:P=0.000;CD13:P=0.003）.4.Kaplan-Meier analysis showed that the OS time was significantly shortened in MM patients in the CD56^-group than in the CD56⁺group（21 vs 25 months,P=0.021）;the OS time was significantly shortened in MM patients in the calcium≥2.75 group than in the calcium<2.75 group（22 vs 24 months,P=0.028）;the OS time was significantly shortened in MM patients in the LDH≥245 group than in the LDH<245group（23 vs 25 months,P=0.023）;the OS time was significantly shortened in MM patients in theβ2-MG≥5.5 group than in theβ2-MG<5.5 group（20 vs 25 months,P=0.008）;the OS time was significantly shortened in MM patients in the1q21 amplification group than in the no 1q21 amplification group（20 vs 25 months,P=0.008）;the OS time was significantly shortened in MM patients in the RB1 deletion group than in the no RB1 deletion group（20 vs 30.5 months, P=0.029）;the OS time was significantly shortened in MM patients in the P53 eletion group than in the no P53 deletion group（17.5 vs 22 months,P=0.000）;the OS time was significantly shortened in MM patients in the ISS stageⅢgroup han in the ISS stageⅠ/Ⅱgroup（19.5 vs 25 months,P=0.023）.5.Cox egression analysis showed that 1q21 amplification（P=0.002）,RB1 deletion（P=0.001）,P53 deletion（P=0.013）were independent adverse prognostic factors in MM patients.Conclusion 1.CD33 and CD13 are prognostic risk factors in patients with MM.2.1q21 amplification,RB1 deletion and P53 deletion were also prognostic risk factors in MM patients.